bioMérieux S.A. reported earnings results for the half year ended June 30, 2025. For the half year, the company reported sales was EUR 2,043.8 million compared to EUR 1,901.9 million a year ago. Sales was EUR 2,043.8 million compared to EUR 1,901.9 million a year ago.
Net income was EUR 161 million compared to EUR 215.3 million a year ago. Net income was EUR 161 million compared to EUR 215.3 million a year ago. Basic earnings per share from continuing operations was EUR 1.36 compared to EUR 1.83 a year ago.
Basic earnings per share from continuing operations was EUR 1.36 compared to EUR 1.83 a year ago. Diluted earnings per share from continuing operations was EUR 1.35 compared to EUR 1.82 a year ago. Diluted earnings per share from continuing operations was EUR 1.35 compared to EUR 1.82 a year ago.
bioMérieux designs, develops, produces, and sells systems used in clinical practice to diagnose infectious diseases (including HIV, tuberculosis, and respiratory infections), cancers, and cardiovascular pathologies based on a biological sample (blood, saliva, urine, etc.). Net sales break down by sector of application as follows:
- medical applications (84.8%): in industry, microbiological testing of samples from finished products, materials during the manufacturing process, or the environment, primarily in the food-processing, pharmaceutical, and cosmetics sectors;
- industrial applications (15.2%).
The group's diagnostic systems consist of three elements with related services: reagents, instruments (or platforms or analyzers), software, and services.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (31.9%), North America (45%), Asia/Pacific (16,5%) and Latin America (6.6%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
